ADR

By Targets:	Adrenergic Receptor (1) Akt (2) Apoptosis (4) Autophagy (1) Bcl-2 Family (1) Carbonic Anhydrase (1) Caspase (1) Cholinesterase (ChE) (1) DNA/RNA Synthesis (1) Dopamine Receptor (1) Estrogen Receptor/ERR (1) HBV (1) iGluR (1) Interleukin Related (2) Keap1-Nrf2 (1) Melanocortin Receptor (1) Microtubule/Tubulin (2) Neuropeptide Y Receptor (1) P-glycoprotein (4) p38 MAPK (1) PARP (1) PI3K (1) Potassium Channel (1) Sigma Receptor (1) Wnt (1) β-catenin (1)
By Research Areas:	Cancer (16) Cardiovascular Disease (2) Infection (2) Inflammation/Immunology (2) Metabolic Disease (1) Neurological Disease (4)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-76201

Dexrazoxane hydrochloride Maximum Cited Publications 8 Publications Verification ICRF-187 hydrochloride; ADR-529 hydrochloride; NSC-169780 hydrochloride	Others	Cardiovascular Disease Cancer
Dexrazoxane hydrochloride (ICRF-187 hydrochloride) is a cardioprotective agent.

HY-B0581

Dexrazoxane Maximum Cited Publications 8 Publications Verification ICRF-187; ADR-529; NSC-169780	Others	Cardiovascular Disease Cancer
Dexrazoxane (ICRF-187) is a cardioprotective agent.

HY-101747A

ADR 851

Dopamine Receptor Neurological Disease

ADR 851 is a dopamine D2 receptor antagonist,and can be used in research on antiemetics .

ADR 851	Dopamine Receptor	Neurological Disease
ADR 851 is a dopamine D2 receptor antagonist,and can be used in research on antiemetics .

HY-148695B

ADR58 sodium	Interleukin Related	Inflammation/Immunology
ADR58 sodium is a highly potent and selective human oncostatin M (OSM) antagonist, which can prevent the binding of OSM to the gp130 receptor and specifically antagonize OSM-mediated signaling. ADR58 sodium can be used in the research of rheumatoid arthritis related diseases .

HY-148695C

*Truncated ADR58 sodium*	Interleukin Related	Inflammation/Immunology
ADR58 sodium is a highly potent and selective human oncostatin M (OSM) antagonist, which can prevent the binding of OSM to the gp130 receptor and specifically antagonize OSM-mediated signaling. ADR58 sodium can be used in the research of rheumatoid arthritis related diseases .

HY-10815

σ1 Receptor antagonist-1 1 Publications Verification	Sigma Receptor Apoptosis	Neurological Disease Cancer
σ1 Receptor antagonist-1 is a highly potent and selective sigma 1 receptor antagonist (pK_i=10.28). σ1 Receptor antagonist-1 inhibits cell growth, arrests cell cycle at G0/G1 phase and induces apoptosis of MCF-7/ADR cells .

HY-149360

P-gb-IN-1	P-glycoprotein	Cancer
P-gb-IN-1 (compound Ⅲ-8), a 2,5-disubstituted furan derivative, is a highly effective, broadspectrum P-glycoprotein (P-gp) inhibitor. P-gb-IN-1 displayed the reversal activity by inhibiting P-gp efflux. P-gb-IN-1 has a potent affinity to P-gp by forming H-bond interactions with residues Asn 721 and Met 986. P-gb-IN-1 possesses broad-spectrum reversal activity and low toxicity in MCF-7/ADR cells .

HY-114803

Kokusaginine	Cholinesterase (ChE) Apoptosis Microtubule/Tubulin	Neurological Disease Cancer
Kokusaginine is a furoquinoline alkaloids, which exhibits inhibitory efficacy for acetylcholinesterase (AChE) with an IC₅₀ of 28.2 μM. Kokusaginine exhibits anti-proliferative and apoptotic inducing effects in MCF-7/ADR cells .

HY-N3584

Paris saponin VII 1 Publications Verification Chonglou Saponin VII	Akt p38 MAPK P-glycoprotein Bcl-2 Family Caspase PARP Autophagy Apoptosis	Cancer
Paris saponin VII (Chonglou Saponin VII) is a steroidal saponin isolated from the roots and rhizomes of Trillium tschonoskii. Paris saponin VII-induced apoptosis in K562/ADR cells is associated with Akt/MAPK and the inhibition of P-gp. Paris saponin VII attenuates mitochondrial membrane potential, increases the expression of apoptosis-related proteins, such as Bax and cytochrome c, and decreases the protein expression levels of Bcl-2, caspase-9, caspase-3, PARP-1, and p-Akt. Paris saponin VII induces a robust autophagy in K562/ADR cells and provides a biochemical basis in the treatment of leukemia .

HY-12458

Pyrindamycin A	DNA/RNA Synthesis	Infection Cancer
Pyrindamycin A is an antibiotic that inhibits DNA synthesis. Pyrindamycin A shows antitumor activities against murine leukemia, exhibits stronger cytotoxic activities towards murine and human tumor cell lines and especially towards doxorubicin-resistant cells, inhibits P388 and P388/ADR cells with the same IC₅₀ of 3.9 μg/ml .

HY-125136

Chaetominine (-)-Chaetominine	PI3K Akt Keap1-Nrf2	Cancer
Chaetominine is an alkaloidal metabolite. Chaetominine has cytotoxicity against human leukemia K562 and colon cancer SW1116 cell lines. Chaetominine reduces MRP1-mediated agent resistance via inhibiting PI3K/Akt/Nrf2 signaling pathway in K562/Adr human leukemia cells .

HY-161260

P-gp inhibitor 20	P-glycoprotein	Cancer
P-gp inhibitor 20 (compound H27) is a low cytotoxicity P-glycoprotein (P-gp) inhibitor. P-gp inhibitor 20 inhibits the efflux function of P-gp in a dose-dependent manner (without affecting the expression of P-gp), thereby reversing the multidrug resistance (MDR) of MCF-7/ADR cells, with an IC₅₀ value of 46.6 nM. P-gp inhibitor 20 can be used for cancer research .

HY-144306

ERα degrader 4	Estrogen Receptor/ERR Apoptosis	Cancer
ERα degrader 4 is an excellent and selective estrogen receptor α (ERα) degrader (IC₅₀ of 0.31, 0.41 and 0.48 μM in MDA-MB-231, MCF-7 and MCF-7/ADR cells, respectively). ERα degrader 4 has potent inhibitory activity against MCF-7 cell lines. ERα degrader 4 is a potential SERDs candidate for the research of breast cancer .

HY-135014

Undecylenoyl phenylalanine	Melanocortin Receptor Adrenergic Receptor	Others
Undecylenoyl phenylalanine is an antagonist for α-melanocyte-stimulating hormone (MSH) and β-adrenergic receptor (β-ADR) to reduce the melanogenesis in melanocytes, reduces hyperpigmentation and thus ameliorates melasma lesions and solar lentigines .

HY-126123

NR2B-selective NMDA receptor antagonist 1	iGluR Potassium Channel	Neurological Disease
NR2B-selective NMDA receptor antagonist 1 (compound 29) is a potent antagonist of NR1/NR2B receptors, with IC₅₀s of 0.05 μM, 0.73 μM, 2.4 μM to NR1/NR2B NMDA receptor, hERG, α1-AdR, respectivity. NR2B-selective NMDA receptor antagonist 1 exhibites efficient permeability across the blood–brain barrier .

HY-N1665

2',4'-Dihydroxy-3',6'-dimethoxychalcone	Others	Cancer
2',4'-Dihydroxy-3',6'-dimethoxychalcone is a natural product that can be isolated from Polygonum Lapathifolium. 2',4'-Dihydroxy-3',6'-dimethoxychalcone inhibits the growth of CCRF-CEM leukaemia cells and CEM/ADR5000 cells, with IC₅₀ values of 10.67 and 18.60 μM, respectively .

HY-157464

[Ru(phen)2(4-Me-Sal)]BF4	Others	Cancer
[Ru(phen)2(4-Me-Sal)]BF4 (compound 10), a Ru(II)-based polypyridyl complexe, displays outstanding antiproliferative activity against drug-sensitive CCRF-CEM and multidrug-resistant CEM/ADR5000 leukemia cells (IC₅₀=0.52 μM and 5.56 μM, respectively) .

HY-101986A

BIIE-0246 hydrochloride AR-H 053591 hydrochloride	Neuropeptide Y Receptor	Metabolic Disease
BIIE-0246 hydrochloride (AR-H 053591 hydrochloride) is a potent and selective NPY2R (neuropeptide Y receptor 2) antagonist with an IC₅₀ value of 15 nM for rat [ ¹²⁵I]PYY_3-36. BIIE-0246 hydrochloride decreases the expression of p-AKT S473, P-p44/42 MAPK under the NPY-stimulated. BIIE-0246 hydrochloride reduces albuminuria in ADR nephropathy .

HY-N1365

Isoscopoletin 6-Hydroxy-7-methoxycoumarin	HBV	Infection Cancer
Isoscopoletin (6-Hydroxy-7-methoxycoumarin) is an active constituent in Artemisia argyi leaves. Isoscopoletin shows substantial inhibition against cell proliferation, with IC₅₀s of 4.0 μM and 1.6 μM for human CCRF-CEM leukaemia cells and multidrug resistant subline CEM/ADR5000, respectively . Isoscopoletin (6-Hydroxy-7-methoxycoumarin) possesses inhibitory activity against HBV replication .

HY-12892

SKI-178
SKI-178 is a potent sphingosine kinase-1 (SphK1) and SphK2 inhibitor. SKI-178 is cytotoxic at IC₅₀ concentrations ranging from 1.8 to 0.1 μM in both agent sensitive and multi-agent resistant cancer cell lines (i.e., MTR3, NCI-ADR and HL60/VCR cells). SKI-178 induces apoptosis in a CDK1-dependent manner in human acute myeloid leukemia cell lines .

HY-155391

hCA/Wnt/β-catenin-IN-1	Carbonic Anhydrase P-glycoprotein Wnt β-catenin	Cancer
hCA/Wnt/β-catenin-IN-1 (Compd 15) is an inhibitor of hCA (K_i: 33.6, 24.1, 6.8 nM for hCA II, hCA IX, hCA XII). hCA/Wnt/β-catenin-IN-1 reduces P-gp activity. hCA/Wnt/β-catenin-IN-1 also inhibits Wnt/β-catenin signaling pathway. hCA/Wnt/β-catenin-IN-1 inhibits cancer cell viability, including the NCI/ADR-RES DOX-resistant cell line .

HY-N10621

3,5-Dimethoxy-2,7-phenanthrenediol	Others	Cancer
3,5-Dimethoxy-2,7-phenanthrenediol (compound 2) is a phenanthrene compound isolated from the roots of Combretum laxum. 3,5-Dimethoxy-2,7-phenanthrenediol is cytotoxic to human cancer cell lines 786-0, MCF-7 and NCI/ADR-RES, with IC₅₀s of 73.26 μM, 118.40 μM and 83.99 μM respectively. 3,5-Dimethoxy-2,7-phenanthrenediol also has free radical scavenging activity with an IC₅₀ of 20.4 μM .

HY-149388

Anticancer agent 139	Microtubule/Tubulin	Cancer
Anticancer agent 139 (Compound 6h) has potent anticancer activity. Anticancer agent 139 displayed a π–cationic interaction with the residue Lys352 of Tublin. Anticancer agent 139 has good anticancer activity against SNB-19, OVCAR-8, and NCI-H40 with PGIs of 86.61, 85.26, and 75.99, respectively. Anticancer agent 139 also has moderate anticancer activity against HOP-62, SNB-75, ACHN, NCI/ADR-RES, 786-O, A549/ATCC, HCT-116, and MDA-MB-231 with PGIs of 67.55, 65.46, 59.09, 59.02, 57.88, 56.88, 56.53, 56.4, and 51.88 respectively .

Cat. No.	Product Name

HY-L140

Withdrawn Drug Compound Library	198 compounds
Withdrawal or delisting drugs refer to drugs that are recalled or discontinued from the market due to low efficiency, serious side effects, financial and regulatory problems and other reasons. Once the drug is withdrawn from the market, it will cause heavy losses to the original research company that invested a lot of time, finance and other costs to develop the drug. Adverse drug reaction (ADR) is the main reason for drug withdrawal from the market. ADR refers to the unexpected effects caused by the reasons such as the target-directed interaction during the treatment. However, studying the mechanism of these ADRs may just be a breakthrough in finding new indications. For example, thalidomide, the protagonist of the drug damage event that caused numerous "seal babies" deformed infants, was found to be due to the degradation of a transcription factor - SALL4 after delisting, which made thalidomide have a new clinical application. In 1998, it was approved by FDA for the treatment of leprosy nodular erythema, and in 2006, it was approved for the treatment of multiple myeloma. ADR study of delisted drugs can not only avoid the loss of drug development in advance but also bring hope to new indications. MCE has sorted out 198 drug compounds withdrawn from the market through FDA, EMA and other authoritative platforms. Each compound has withdrawal records in at least one country/market. It is a useful tool for conducting research on drug side effects or drug toxicity mechanisms and discovering new indications of drugs.

Withdrawn Drug Compound Library

198 compounds

Withdrawal or delisting drugs refer to drugs that are recalled or discontinued from the market due to low efficiency, serious side effects, financial and regulatory problems and other reasons. Once the drug is withdrawn from the market, it will cause heavy losses to the original research company that invested a lot of time, finance and other costs to develop the drug.

Adverse drug reaction (ADR) is the main reason for drug withdrawal from the market. ADR refers to the unexpected effects caused by the reasons such as the target-directed interaction during the treatment. However, studying the mechanism of these ADRs may just be a breakthrough in finding new indications. For example, thalidomide, the protagonist of the drug damage event that caused numerous "seal babies" deformed infants, was found to be due to the degradation of a transcription factor - SALL4 after delisting, which made thalidomide have a new clinical application. In 1998, it was approved by FDA for the treatment of leprosy nodular erythema, and in 2006, it was approved for the treatment of multiple myeloma. ADR study of delisted drugs can not only avoid the loss of drug development in advance but also bring hope to new indications.

MCE has sorted out 198 drug compounds withdrawn from the market through FDA, EMA and other authoritative platforms. Each compound has withdrawal records in at least one country/market. It is a useful tool for conducting research on drug side effects or drug toxicity mechanisms and discovering new indications of drugs.

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N3584

Paris saponin VII 1 Publications Verification Chonglou Saponin VII	Liliaceae Classification of Application Fields Source classification Trillium tschonoskii Maxim. Plants Disease Research Fields Steroids Cancer	Akt p38 MAPK P-glycoprotein Bcl-2 Family Caspase PARP Autophagy Apoptosis
Paris saponin VII (Chonglou Saponin VII) is a steroidal saponin isolated from the roots and rhizomes of Trillium tschonoskii. Paris saponin VII-induced apoptosis in K562/ADR cells is associated with Akt/MAPK and the inhibition of P-gp. Paris saponin VII attenuates mitochondrial membrane potential, increases the expression of apoptosis-related proteins, such as Bax and cytochrome c, and decreases the protein expression levels of Bcl-2, caspase-9, caspase-3, PARP-1, and p-Akt. Paris saponin VII induces a robust autophagy in K562/ADR cells and provides a biochemical basis in the treatment of leukemia .

HY-N1365

Isoscopoletin 6-Hydroxy-7-methoxycoumarin	Structural Classification Classification of Application Fields Source classification Coumarins Plants Compositae Infection Monophenols other families Phenols Phenylpropanoids Disease Research Fields Sindora sumatrana Miq. Cancer	HBV
Isoscopoletin (6-Hydroxy-7-methoxycoumarin) is an active constituent in Artemisia argyi leaves. Isoscopoletin shows substantial inhibition against cell proliferation, with IC₅₀s of 4.0 μM and 1.6 μM for human CCRF-CEM leukaemia cells and multidrug resistant subline CEM/ADR5000, respectively . Isoscopoletin (6-Hydroxy-7-methoxycoumarin) possesses inhibitory activity against HBV replication .

HY-114803

Kokusaginine	Structural Classification Alkaloids Source classification Rutaceae Quinoline Alkaloids Melicope pteleifolia (Champ. ex Benth.) Hartley Plants	Cholinesterase (ChE) Apoptosis Microtubule/Tubulin
Kokusaginine is a furoquinoline alkaloids, which exhibits inhibitory efficacy for acetylcholinesterase (AChE) with an IC₅₀ of 28.2 μM. Kokusaginine exhibits anti-proliferative and apoptotic inducing effects in MCF-7/ADR cells .

HY-N1665

2',4'-Dihydroxy-3',6'-dimethoxychalcone	Flavonoids Chalcones Classification of Application Fields Polygonaceae Source classification Phenols Polyphenols Plants Disease Research Fields Perilla ocimoides L. Cancer	Others
2',4'-Dihydroxy-3',6'-dimethoxychalcone is a natural product that can be isolated from Polygonum Lapathifolium. 2',4'-Dihydroxy-3',6'-dimethoxychalcone inhibits the growth of CCRF-CEM leukaemia cells and CEM/ADR5000 cells, with IC₅₀ values of 10.67 and 18.60 μM, respectively .

HY-N10621

3,5-Dimethoxy-2,7-phenanthrenediol	Structural Classification Combretaceae Phenols Polyphenols Plants Quisqualis indica Linn.	Others
3,5-Dimethoxy-2,7-phenanthrenediol (compound 2) is a phenanthrene compound isolated from the roots of Combretum laxum. 3,5-Dimethoxy-2,7-phenanthrenediol is cytotoxic to human cancer cell lines 786-0, MCF-7 and NCI/ADR-RES, with IC₅₀s of 73.26 μM, 118.40 μM and 83.99 μM respectively. 3,5-Dimethoxy-2,7-phenanthrenediol also has free radical scavenging activity with an IC₅₀ of 20.4 μM .

Cat. No.	Compare	Product Name	Species	Source

HY-P74728

	*NA/Neuraminidase Protein, H1N2 (ADR51655, HEK293, His)* Influenza A H1N2 (A/swine/Italy/191985/2009) Neuraminidase / NA (HEK293, His)	Virus	HEK293
	NA/Neuraminidase Protein is a receptor-destroying enzyme that cleaves terminal sialic acids from cellular receptors, potentially facilitating viral invasion of the upper airways by targeting sialic acid moieties on airway epithelial cell mucin. NA plays a pivotal role in viral propagation by catalyzing the removal of terminal sialic acid residues from both viral and cellular glycoconjugates. Moreover, the sialidase activity in late endosome/lysosome traffic appears to enhance virus replication. NA/Neuraminidase Protein, H1N2 (ADR51655, HEK293, His) is the recombinant Virus-derived NA/Neuraminidase protein, expressed by HEK293 , with N-His labeled tag. The total length of NA/Neuraminidase Protein, H1N2 (ADR51655, HEK293, His) is 434 a.a., with molecular weight of ~50.7 kDa.


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Application	Reactivity

HY-P80005

Adiponectin receptor protein 1 Antibody ACDCR1; ADIPO R1; Adiponectin receptor protein 1; ADIPOR 1; ADIPOR1; CGI-45; CGI-45 protein; FLJ25385; PAQR1; Progestin and adipoQ receptor family member I; TESBP1A; ADR1_HUMAN.	ICC/IF, IHC-P, FC	Human, Mouse
Adiponectin receptor protein 1 Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 43 kDa, targeting to Adiponectin receptor protein 1. It can be used for ICC/IF,IHC-P,FC assays with tag free, in the background of Human, Mouse.

HY-P81338

Aldose Reductase Antibody (YA1083)

AR; ADR; ALR2; ALDR1
WB Human, Mouse, Rat

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inhibitors & Agonists

Screening Libraries

Natural
Products

Recombinant Proteins

Antibodies